Status:
COMPLETED
A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies, regular treatment with SERETIDE in a stable dosing with short a...
Detailed Description
The purpose with this study is to describe in detail the control or lack of control of asthma, based on two different dosing strategies. No therapy intervention is made with existing prescribed medica...
Eligibility Criteria
Inclusion
- written informed consent
- 18 years or above
- able to fill in questionnaires and perform PEF measurements
- asthma diagnosis and prescribed SERETIDE or SYMBICORT, either regular treatment using SERETIDE in a stable dosing and short acting B2 agonists as needed, or maintenance treatment with SYMBICORT but also using same inhaler SYMBICORT as needed
Exclusion
- no other lung disease
- neurological disease with psychological handicap
- cerebro-vascular disease with handicap
- un-stable cancer
- known or planned pregnancy during the time of the study
- subjects who have serious uncontrolled disease
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00858286
Start Date
February 1 2009
End Date
April 1 2010
Last Update
August 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Stockholm, Sweden, SE-171 77